Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: Results from the impact rcc claims data analysis

Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: Results from the impact rcc claims data analysis

BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment is delayed disease progression. The degree to which early therapeutic success affects downstream outcomes is not well established. OBJECTIVE: To assess the clinical and economic impact of early vs delayed disease...

Full description

Bibliographic Details
Main Authors: Bhanegaonkar, A. (Author), Dieyi, C. (Author), Hutson, T.E (Author), Kasturi, V. (Author), Kim, R. (Author), Krulewicz, S. (Author), Liu, F.X (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
aged
Article
cancer patient
cancer survival
Carcinoma, Renal Cell
clinical outcome
confidence interval
confounding variable
data analysis
data base
disease exacerbation
Disease Progression
female
follow up
hazard ratio
health care cost
Health Care Costs
health economics
human
Humans
insurance
Insurance Claim Review
Kaplan Meier method
kidney metastasis
length of stay
major clinical study
male
metastasis
Neoplasm Metastasis
Outcome Assessment, Health Care
overall survival
proportional hazards model
protein kinase inhibitor
Protein Kinase Inhibitors
protein tyrosine kinase inhibitor
renal cell carcinoma
Retrospective Studies
retrospective study
veterans health
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items